Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year

MT Newswires Live11-18

Cybin (CYBN) said Monday that data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers "sustained relief" through one year.

By 12 months, response rates for two 16-milligram doses of the drug given three weeks apart were 100% while 71% of the eight study participants were in remission, the company said.

Cybin said it recently initiated a phase 3 trial to evaluate CYB003's effectiveness and safety in a larger number of patients. The drug earlier received Breakthrough Therapy Designation from the US Food and Drug Administration for major depressive disorder, Cybin added.

The company also said it expects to report phase 2 results for CYB004 as a potential treatment for generalized anxiety disorder in Q1.

Cybin shares were up 11% in recent premarket activity.

Price: 12.89, Change: +1.29, Percent Change: +11.12

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484221386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484221386","market":"us","top_or_hot":-1,"title":"Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year","media":"MT Newswires Live","content":"<html><body><p> Cybin (CYBN) said Monday that data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers \"sustained relief\" through one year.</p><p>By 12 months, response rates for two 16-milligram doses of the drug given three weeks apart were 100% while 71% of the eight study participants were in remission, the company said.</p><p>Cybin said it recently initiated a phase 3 trial to evaluate CYB003's effectiveness and safety in a larger number of patients. The drug earlier received Breakthrough Therapy Designation from the US Food and Drug Administration for major depressive disorder, Cybin added.</p><p>The company also said it expects to report phase 2 results for CYB004 as a potential treatment for generalized anxiety disorder in Q1.</p><p>Cybin shares were up 11% in recent premarket activity.</p><p>Price: 12.89, Change: +1.29, Percent Change: +11.12</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cybin (CYBN) said Monday that data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers \"sustained relief\" through one year.By 12 months, ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4168","symbol_name":"多种金属与采矿","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484221386","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484221386","pubTimestamp":1731935385,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cybin  said Monday that data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers \"sustained relief\" through one year.By 12 months, response rates for two 16-milligram doses of the drug given three weeks apart were 100% while 71% of the eight study participants were in remission, the company said.Cybin said it recently initiated a phase 3 trial to evaluate CYB003's effectiveness and safety in a larger number of patients. The drug earlier received Breakthrough Therapy Designation from the US Food and Drug Administration for major depressive disorder, Cybin added.The company also said it expects to report phase 2 results for CYB004 as a potential treatment for generalized anxiety disorder in Q1.Cybin shares were up 11% in recent premarket activity.Price: 12.89, Change: +1.29, Percent Change: +11.12","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4168":"多种金属与采矿","CYBN":"Cybin Inc","BK4007":"制药"},"translate_title":"Cybin表示，第二阶段数据显示潜在的抑郁症药物可在1年内缓解症状","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYBN":0.9},"content_text":"Cybin (CYBN) said Monday that data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers \"sustained relief\" through one year.By 12 months, response rates for two 16-milligram doses of the drug given three weeks apart were 100% while 71% of the eight study participants were in remission, the company said.Cybin said it recently initiated a phase 3 trial to evaluate CYB003's effectiveness and safety in a larger number of patients. The drug earlier received Breakthrough Therapy Designation from the US Food and Drug Administration for major depressive disorder, Cybin added.The company also said it expects to report phase 2 results for CYB004 as a potential treatment for generalized anxiety disorder in Q1.Cybin shares were up 11% in recent premarket activity.Price: 12.89, Change: +1.29, Percent Change: +11.12","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484221386"}